Immune function and the risk of cvd among HIV infected and uninfected veterans

HIV感染者和未感染者的免疫功能和CVD风险

• 批准号: 8790187
• 负责人: MATTHEW S FREIBERG
• 金额: $ 75.43万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-27 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8790187
• 关键词: Acute myocardial infarction; Aging; Anemia; Anti-Retroviral Agents; Atherosclerosis; Biological Markers; Blood; CD14 gene; CD4 Positive T Lymphocytes; Cardiovascular Diseases; Cause of Death; Cell Count; Cell physiology; Cells; Cessation of life; Clinical; Clinical Pathology; Coagulation Process; Cohort Studies; Communities; Computerized Medical Record; Coronary heart disease; Cryopreserved Cell; Data; Disease; Event; Fee-for-Service Plans; Fibrin fragment D; Future; Grant; HIV; HIV Infections; Health; Healthcare Systems; Heart Diseases; Heart failure; Hematological Disease; Hepatitis C; Human; Immune; Immune system; Infection; Inflammation; Interleukin-6; Intervention Studies; Ischemic Stroke; Justice; Kidney Diseases; Laboratories; Link; Longitudinal Surveys; Lung diseases; Measurement; Measures; Mediating; Medicare/Medicaid; Memory; Modeling; Morbidity - disease rate; Mus; Participant; Pathogenesis; Peripheral; Pharmacy facility; Prevalence; Protocols documentation; Radiology Specialty; Records; Research; Research Infrastructure; Resources; Risk; Risk Factors; T memory cell; T-Lymphocyte; T-Lymphocyte Subsets; Testing; Veterans; adjudicate; antiretroviral therapy; base; cardiovascular disorder risk; cardiovascular risk factor; cell type; cohort; experience; heart disease risk; high risk; immune function; immunosenescence; improved; indexing; insight; interest; lipid metabolism; monocyte; mortality; peripheral blood; prospective; public health relevance; success; tool

DESCRIPTION (provided by applicant): With improving long-term survival after successful suppression of HIV replication, cardiovascular disease (CVD) is an increasingly important health problem facing HIV infected (HIV+) people. Antiretroviral therapy itself, conventional Framingham risk factors, anemia, hepatitis C co-infection, and renal disease are all risk factors among HIV+ people, but these factors do not completely explain the excess risk of CVD among HIV+ compared to uninfected (HIV-) people. Based on insights gained largely from murine models, progressive atherosclerosis largely causes CVD which is in turn caused by inappropriate lipid metabolism and activation of the innate and adaptive immune systems. While alteration in immune cell function is a shared feature of HIV and CVD pathogenesis, it is not known whether the activation, number and or proportion of peripheral circulating monocyte and T cell subsets are associated with incident CVD in humans and explain the excess risk of CVD among HIV+ people compared to HIV- people. To answer these questions, we will leverage the Veterans Aging Cohort Study (VACS) biomarker cohort, a longitudinal, prospective observational cohort of 1525 HIV+ and 853 HIV- Veterans. Important strengths of this cohort include existing stored cryopreserved cells, data on biomarkers of inflammation, coagulation, and monocyte activation; longitudinal survey, Medicare, Medicaid, mortality and national death index data; comprehensive access to the entire VA electronic medical record including pharmacy records; and adjudicated CVD events occurring within and outside the VA. We propose to measure immune cell types and subsets from existing cryopreserved cells collected in 2005-2006 and (2) to adjudicate CVD events (i.e., acute myocardial infarction, coronary heart disease, ischemic stroke, heart failure, and CVD death) from 2005-2017. Our specific aims are to: (1) Determine the number and proportion of pro and anti-atherosclerotic immune cells as well as naive and memory/effector T cells among HIV+ and HIV- people; (2) Determine if these immune cell types and subsets are independently associated with prevalent and incident CVD; (3) Determine whether they mediate the association between HIV infection and incident CVD. We hypothesize that people with (1) a higher proportion of proatherosclerotic (e.g., intermediate monocytes and TH1 cells) and a lower proportion of anti-atherosclerotic (e.g., TH regulatory cells) immune cells, respectively, and/or (3) increased evidence of immunosenescence (e.g., a low ratio of naive: memory T cells) will have an increased risk of incident CVD and that these types of immune cell subsets will explain the excess risk of CVD among HIV+ people compared to HIV- people. If our hypotheses are true, we will advance our understanding of how immune function contributes to CVD for HIV+ and HIV- people while also potentially identifying new targets for future CVD intervention studies and new risk factors for inclusion into current CVD risk prediction tools. In addition, the VACS biomarker cohort will become a valuable resource for the larger research community interested in immune function and CVD and other lung and blood disorders.

描述（由申请人提供）：随着成功抑制HIV复制后长期生存率的提高，心血管疾病（CVD）是HIV感染者（HIV+）面临的日益重要的健康问题。抗逆转录病毒治疗本身，常规的Fragrance风险因素，贫血，丙型肝炎合并感染和肾脏疾病都是HIV+人群的风险因素，但这些因素并不能完全解释HIV+人群与未感染（HIV-）人群相比CVD的风险增加。基于主要从鼠模型获得的见解，进行性动脉粥样硬化主要引起CVD，CVD又由不适当的脂质代谢和先天性和适应性免疫系统的激活引起。虽然免疫细胞功能的改变是HIV和CVD发病机制的共同特征，但尚不清楚外周循环单核细胞和T细胞亚群的活化、数量和/或比例是否与人类中的CVD事件相关，并解释HIV+人群与HIV-人群相比CVD的过度风险。为了回答这些问题，我们将利用退伍军人衰老队列研究（VACS）生物标志物队列，这是一个纵向的前瞻性观察队列，包括1525名HIV+和853名HIV-退伍军人。该队列的重要优势包括现有储存的冷冻保存细胞，炎症，凝血和单核细胞活化生物标志物的数据;纵向调查，医疗保险，医疗补助，死亡率和国家死亡指数数据;全面访问整个VA电子病历，包括药房记录;以及VA内外发生的裁定CVD事件。我们建议从2005 - 2006年收集的现有冷冻保存细胞中测量免疫细胞类型和亚群，以及（2）判定CVD事件（即，急性心肌梗死、冠心病、缺血性卒中、心力衰竭和CVD死亡）。我们的具体目标是：（1）确定HIV+和HIV-人群中促动脉粥样硬化和抗动脉粥样硬化免疫细胞以及幼稚和记忆/效应T细胞的数量和比例;（2）确定这些免疫细胞类型和亚群是否与流行和偶发CVD独立相关;（3）确定它们是否介导HIV感染和偶发CVD之间的关联。我们假设：（1）动脉粥样硬化前病变比例较高的人（例如，中等单核细胞和TH1细胞）和较低比例的抗动脉粥样硬化（例如，TH调节细胞）免疫细胞，和/或（3）免疫衰老的证据增加（例如，低比例的幼稚：这些免疫细胞亚群将增加CVD发病的风险，并且这些类型的免疫细胞亚群将解释HIV+人群与HIV-人群相比CVD的过度风险。如果我们的假设是真的，我们将进一步了解免疫功能如何有助于HIV+和HIV-人群的CVD，同时还可能为未来的CVD干预研究确定新的目标，并将新的风险因素纳入当前的CVD风险预测工具。此外，VACS生物标志物队列将成为对免疫功能和CVD以及其他肺部和血液疾病感兴趣的更大研究社区的宝贵资源。